Project Grant R01AI198969
Award Date 8/6/26
Completion Date 7/31/31
Dollars Obligated $619K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pullman, WA 99164, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $191,376 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map escape mutations in respiratory syncytial virus fusion protein and monitor for antibody-resistant viral strains. The recipient will develop a deep mutational scanning platform to comprehensively measure the effects of all possible mutations on cell entry and neutralization by clinically...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $296,414 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate effector-triggered inflammasome activation in rotavirus host defense and viral pathogenesis. The research addresses rotavirus as the primary cause of severe dehydrating diarrhea in children under age five, responsible for approximately two million hospitalizations and over 200,000 deaths...
- The National Institute of Allergy and Infectious Diseases awarded Washington State University $497,779 on February 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of the FN-14 receptor in TNF-induced inflammation and tissue destruction, with performance through January 31, 2031. The research addresses the partial ineffectiveness of TNF-alpha inhibitors in treating rheumatoid arthritis and related inflammatory diseases in over 40...
- The National Institute of Allergy and Infectious Diseases awarded $264,750 to the University of Washington on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of three transcriptional regulators—DR1, DRAP1, and BTAF1—in suppressing interferon responses triggered by self-RNA ligands. The research characterizes how loss of these proteins induces robust interferon responses and explores the immunostimulatory double-stranded RNA...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $853,847 to Massachusetts General Hospital on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds characterization of virologic and immunologic features of RSV immunoprophylaxis and escape. The recipient will sequence the genomes of approximately 3,000 biobanked and prospectively collected respiratory syncytial virus...
- The National Institute of Allergy and Infectious Diseases awarded Sciogen LLC $314,363 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel therapeutics targeting respiratory syncytial virus (RSV) infection through G-receptor binding inhibition. The Phase I Small Business Innovation Research award funds evaluation of a new class of RSV inhibitors identified through high-throughput screening. Work includes assessment of biological...
- The National Institute of Allergy and Infectious Diseases awarded Eastern Washington University $168,554 on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to determine the role of the glucocorticoid receptor in phagocyte pro-inflammatory responses. The research investigates how endogenous glucocorticoid signaling regulates macrophage and neutrophil responses to pathogens, addressing a gap in understanding glucocorticoid biology relevant to developing...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded $902,741 to the University of Washington on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds basic research into the cell type-specific regulation of STING signaling, a central pathway in innate immune response with implications for antiviral immunity, antitumor immunity, and aging-associated inflammation. The research investigates why STING activation produces...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $264,750 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate local B cell immune response to varicella zoster virus infection in shingles patients. The research examines antibody-secreting cells present in shingles lesions, focusing on characterizing virus-specific human monoclonal antibodies derived from tissue biopsies. Prior single-cell RNA...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $427,625 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support basic research on viral infection sensing in C. elegans. The funded research examines how the model organism C. elegans recognizes and responds to RNA virus infection, specifically Orsay virus (ORV), the only known natural virus of this nematode species. The project investigates the host genes...